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Background. The relative impact on renal allograft outcome of specific histological diagnoses versus nonspecific
chronic histological damage remains unclear.
Methods. All 1,197 renal allograft recipients who were transplanted at a single center between 1991 and 2001 were
included. All posttransplant renal allograft indication biopsies performed in this cohort during follow-up (mean,
14.5T2.80 years after transplantation) were rescored according to the current histological criteria and associated with
death-censored graft outcome.
Results. In this cohort, 1,365 allograft indication biopsies were performed. Specific diagnoses were present in 69.4%
of graft biopsies before graft loss, but 30.6% of grafts did not have specific diagnoses in the last biopsy before graft
loss. Only 14.6% of the patients did never have any specific disease diagnosed before graft loss. Extensive interstitial
fibrosis and tubular atrophy without a clear cause was identified as the single cause of graft loss in only 6.9% of the
cases. Acute T-cellYmediated rejection and changes suggestive of acute antibody-mediated rejection, diagnosed after
the first year posttransplant, associated independently with graft survival. Transplant glomerulopathy increased over
time after transplantation and represented a major risk for graft loss, as well as de novo or recurrent glomerular
pathologies and polyomavirus nephropathy. Chronic histological injury associated with graft outcome, independent
of specific diagnoses.
Conclusion. Renal allograft loss is multifactorial. Chronic histological damage and specific diseases had additive and
independent impact on graft outcome. Chronic damage should be taken into account in prognostication of renal
allograft outcome and could be implemented in treatment algorithms for specific diseases of kidney allografts.
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A lthough outcome after kidney transplantation has im-proved over the past decades, renal allograft loss remains
an important clinical problem. The clear improvement in
short-term graft attrition, by better immunosuppression and
prevention of acute rejection, did not translate into propor-
tionate ameliorations of long-term renal allograft survival (1).
To improve long-term graft survival, it is becoming clear that
focusing on strategies to improve short-term outcome are not
sufficient to reach this goal, and that additional strategies need
to be developed. Therefore, it is essential to have a better un-
derstanding of the risk factors for kidney graft failure.
Recent cohort analyses in the United States and Canada
suggested that specific diseases are the main causes of renal
allograft failure (2, 3). These studies illustrated the great im-
portance of antibody-mediated rejection (ABMR) and of de
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novo or recurrent pathologic condition, and plead for more
focus on these specific causes of renal allograft loss. These
studies attributed a single cause to each graft loss. In clinical
practice, however, clinicians are often confronted with com-
plex transplant histories, and the histological interpretation of
renal allografts is often not one-dimensional (4Y6). Especially
late after transplantation, when there is co-occurrence of ex-
tensive chronic damage with specific disease processes, the
interpretation of the histological picture can be cumbersome,
and the prognostic importance of each of the different lesions
or diagnoses in a single biopsy thus remains unclear.
In the current European cohort study, we evaluated
the risk factors of renal allograft loss up to 20 years after
transplantation, taking into account baseline demographics,
the posttransplant clinical history, and the complex histol-
ogy of renal allograft biopsies after the first year post-
transplant, which consists of both specific diagnostic entities
and less specific chronic histological lesions.
RESULTS
Study Population Characteristics
The patient population has been described previously
(N=1,197) (5). All data were collected within standard of
care and routine clinical practice. Mean follow-up time after
transplantation of patients with a functioning graft at time
FIGURE 1. Prevalence over time after transplantation of (A) intragraft diseases, (B) acute histological lesions, and (C)
chronic histological lesions in all 1,365 posttransplant renal allograft biopsies performed for clinical indication in 738 kidney
recipients. Data interpolation was performed using cubic spline curve fitting. A ‘‘normal’’ biopsy was defined as a biopsy
without any specific diagnosis (TCMR, changes suggestive acute ABMR, PVAN, transplant glomerulopathy, glomerular
pathology) and without interstitial fibrosis or tubular atrophy. Other lesions (e.g., glomerulosclerosis, arteriolar hyalinosis)
could be present in these ‘‘normal’’ biopsies. Glomerulosclerosis was scored as follows: 0=0%; 1=1%Y25%; 2=25%Y50%;
3=950% glomerulosclerosis. TCMR, T-cellYmediated rejection; ABMR, antibody-mediated rejection; PVAN, polyomavirus-
associated nephropathy.
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of data extraction was 14.5T2.80 years after transplantation.
Despite acceptable 1-year and 5-year overall graft survival
(90.2% and 78.4%, respectively), 664 grafts were lost during
follow-up, at a mean of 6.81T4.84 years after transplanta-
tion. Graft loss was caused by recipient death with a func-
tioning graft in 351 patients and caused by loss of graft
function in 313 recipients.
Timing and Histology of Biopsies for
Clinical Indication
In the patient cohort of 1,197 transplants, 1,443 post-
transplant indication biopsies were performed in 752 indi-
vidual kidney grafts. Mean time after transplantation of the
biopsies was 1.9T3.4 years (range, 2 days to 18.6 years). Only
78 biopsy samples were of insufficient quality to yield a di-
agnosis and to evaluate according to the Banff scheme, which
left 1,365 biopsies in 738 individual transplants for further
analysis. The baseline demographics of these 738 patients with
biopsies were significantly different from the patients who did
not have biopsies performed, consistent with known risk
factors for posttransplant graft dysfunction. Also, graft survival
was significantly worse in the patient population with at least
one biopsy compared to patients who did not have biopsies
performed (Table S1, SDC, http://links.lww.com/TP/A987).
The prevalence of specific diseases diagnosed in the bi-
opsies of sufficient quality (N=1,365), according to the time
after transplantation, is shown in Figure 1(A) and Table S2
(SDC, http://links.lww.com/TP/A987). Acute T-cellYmediated
rejection (TCMR) and acute ABMR were most prevalent in
the first few weeks after transplantation, and also later after
transplantation, there were a substantial percentage of bi-
opsies that demonstrated acute TCMR and acute ABMR.
Polyomavirus-associated nephropathy (PVAN) was most pre-
valent between 3 months and 2 years after transplantation
and was rare later after transplantation. The prevalence of de
novo or recurrent glomerular diseases increased slowly over
time after transplantation and was diagnosed in 22.5% of graft
biopsies performed after 10 years after transplantation. Simi-
larly, the prevalence of transplant glomerulopathy increased
importantly over time and reached 42.3% prevalence in bi-
opsies performed later than 10 years after transplantation.
Because no lesion or histological pattern is specific for cal-
cineurin inhibitor nephrotoxicity (7) or hypertensive ne-
phropathy, we did not include these diagnoses as separate
entities in our analyses. The mean scores of individual histo-
logical lesions over time after transplantation are provided in
Figure 1(B) to (C).
Biopsy Diagnosis and Graft Outcome
We next evaluated the association of histology after
1 year after transplantation and renal allograft survival. When
a patient had two or more biopsies after 1-year post-
transplant, the last one was used for analysis (N=341 indi-
vidual transplants with at least one biopsy after the first year;
98 patients had 91 late renal allograft biopsy). Graft failure
(not including patient death) occurred in 144 of 341 patients
during follow-up. In multivariate analysis after backward se-
lection, borderline changes and TCMR were significantly
and independently associated with death-censored graft sur-
vival, as well as changes suggestive of acute ABMR, trans-
plant glomerulopathy, and de novo or recurrent glomerular
pathologic condition, adjusted for time after transplantation,
number of prior biopsies, and relevant baseline demographics
(donor and recipient age, type of immunosuppression, trans-
plant year)(Table 1; Fig. 2A). In addition, interstitial fibrosis
TABLE 1. Cox proportional hazards analysis of postbiopsy death-censored graft survival according to the histological
diagnosis of the last biopsy, in univariate and multivariate (backward selection) analyses, in patients with at least one
biopsy after the first posttransplant year (N=341)
Banff scores of the individual
histological lesions
Hazard ratio in univariate
analysis (95% CI)
P value in
univariate analysis
Hazard ratio in multivariate
analysis (95% CI)
P value in
multivariate analysis
TCMR grade
Borderline changes vs. no TCMR 1.73 (1.06Y2.84) 0.03 1.69 (0.99Y2.89) 0.06
TCMR grade 1Y3 vs. no TCMR 3.33 (2.20Y5.04) G0.0001 3.59 (2.25Y5.75) G0.0001
Acute ABMRa 3.69 (2.21Y6.15) G0.0001 2.66 (1.50Y4.74) 0.0009
Transplant glomerulopathya 1.97 (1.31Y2.95) 0.001 1.98 (1.24Y3.16) 0.004
PVANa 2.68 (1.26Y5.70) 0.01 4.07 (1.70Y9.78) 0.002
De novo or recurrent glomerular diseasea 1.32 (0.79Y2.22) 0.28 2.01 (1.18Y3.44) 0.01
Total i score
Grade 1 vs. 0 1.85 (1.13Y3.03) 0.01 V V
Grade 2 vs. 0 3.48 (2.04Y5.93) G0.0001 V V
Grade 3 vs. 0 4.18 (2.59Y6.73) G0.0001 V V
Interstitial fibrosis or tubular atrophy
Grade 1 vs. 0 0.97 (0.59Y1.59) 0.89 1.20 (0.66Y2.16) 0.55
Grade 2 vs. 0 1.69 (1.01Y2.83) 0.05 2.67 (1.48Y4.82) 0.001
Grade 3 vs. 0 2.96 (1.62Y5.41) 0.0004 5.39 (2.69Y10.8) G0.0001
All hazard ratios were adjusted for age of donors and recipients, transplant year, type of immunosuppression, time after transplantation of the biopsy, and
number of previous biopsies. All features included in univariate analysis were included in the multivariate analysis with backward elimination. Total i score
was not retained in the final model after backward selection. Graft failure (not including patient death) occurred in 144 of 341 patients during follow-up.
a Present vs. absent.
TCMR, T-cellYmediated rejection; ABMR, antibody-mediated rejection; PVAN, polyomavirus-associated nephropathy; 95% CI, 95% confidence interval.
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or tubular atrophy grades 2 to 3 was a significant and gradual
determinant of postbiopsy death-censored graft survival, in-
dependent of the presence or absence of a specific disease. Total
i score was highly significant in univariate analysis, but not
retained in the final model after backward elimination because
of the collinearity with specific diseases (Table 1). If the first
FIGURE 2. A, Kaplan-Meier estimates of death-censored graft survival, stratified according to the primary histological
diagnosis in the last biopsy, in all patients with at least one posttransplant biopsy after the first year (N=341). Statistical
evaluation of the association between histological diagnoses and death-censored renal allograft survival is provided in
Table 1. If TCMR was present concomitantly with changes suggestive of acute antibody activity, the latter diagnosis was
retained as primary diagnosis in the Kaplan-Meier visualization. Similarly, when transplant glomerulopathy was present
together with any other rejection diagnosis (TCMR or changes suggestive of acute ABMR), transplant glomerulopathy was
used as primary diagnosis. *IF/TA grade 2Y3 in the absence of any other diagnosis. B, Kaplan-Meier estimates of death-
censored graft survival, stratified according to selected individual histological lesions in last renal allograft biopsies
performed after the first year posttransplantation, in 341 renal allograft recipients. Statistical evaluation of the association
between individual histological lesions and death-censored graft survival, both in univariate and multivariate analyses, is
provided in Table S3, SDC, http://links.lww.com/TP/A987. Mean follow-up time postbiopsy of patients with a functioning
graft at time of data extraction was 6.5T4.7 years. TCMR, T-cellYmediated rejection; ABMR, antibody-mediated rejection; IF/
TA, interstitial fibrosis/tubular atrophy.
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biopsy later than 1 year was used (N=341), instead of the last
biopsy, the conclusions remain similar (data not shown).
Individual Histological Lesions and
Graft Outcome
Next, multivariate adjusted Cox proportional hazards
analysis was performed for prediction of death-censored graft
survival, according to the different histological lesions after
the first posttransplant year (N=341 last biopsies after 1 year).
C4d deposition in peritubular capillaries and transplant glo-
merulopathy, ongoing interstitial inflammation, de novo or
recurrent glomerular disease and chronic histological damage
(interstitial fibrosis and tubular atrophy) were significantly
and independently associated with postbiopsy graft survival
(Fig. 2B; Table S3, SDC, http://links.lww.com/TP/A987). De-
spite being highly significant in univariate analysis, peritubular
capillaritis and glomerulitis, tubulitis, intimal arteritis, total i
score, vascular intimal thickening, mesangial matrix increase,
and glomerulosclerosis were not retained in the final multi-
variate model, consistent with previously identified collinearity
(4, 5) with the other lesions. Interestingly, in last biopsies per-
formed past 1 year after transplantation, arteriolar hyalinosis
comprised an improved outcome.
Histology of Graft Failure
The previous analyses assessed the relative impact of
different specific histological diagnoses and of chronic his-
tological damage on renal allograft outcome. Although these
data suggest that graft failure is multifactorial, we next an-
alyzed the histology of the final biopsies before graft loss. Of
the 313 patients who lost graft function, 257 (82.1%) showed
at least one good-quality indication biopsy before graft loss,
and consequently, 56 (17.9%) patients who lost graft function
did not have any posttransplant biopsy performed. The mean
time of graft failure was 3.2T3.9 (range, 0Y16.4) years after the
last biopsy. Of the patients who lost graft function (N=313),
46% (N=144) had a biopsy within the last 2 years before graft
loss (coincidentally, the same number as the patients with late
biopsies who lost graft function).
Table 2 and Figure 3(B) summarize the histology of
these last 144 biopsies. Importantly, 69.4% (100 of 144) of
graft losses were preceded by a specific histological diagnosis
(including acute TCMR or borderline changes, the single
specific diagnosis in 34 of 144 losses; 27.8%). Of note, 23.6%
(34 of 144) of last biopsies within 2 years before graft loss
showed more than one coexisting specific disease. Later than
5 years after transplantation, transplant glomerulopathy was
the single most observed diagnosis before graft loss, in 35.1%
of patients. In addition, 30.8% of graft losses later than 5 years
were preceded by acute TCMR in the 2 years before graft loss,
which is much higher than the prevalence of this diagnosis
in for-cause biopsies later than 5 years after transplantation
(32 of 205; 15.6%).
Consequently, in 30.6% (44 of 144) of the patients, the
grafts were lost without specific diagnosis in the last biopsy
(Table 2; Fig. 3B). Of these 44 grafts, 23 (52.3%) had a
specific disease in a prior biopsy, whereas 21 did not. Thus,
only 14.6% (21 of 144) of the patients never had any specific
disease diagnosed before graft loss. In retrospective evalua-
tion of the complete medical records of these 21 cases, eight
TABLE 2. Histology of graft failure in 144 last biopsies for clinical indication, performed within the last 2 yr before
graft failure
All Graft loss G1 yr Graft loss 1Y5 yr Graft loss 95 yr
Number of patients with graft loss 313 74 76 163
Number of patients with biopsies within 2 yr of failure (%) 144 (46.0%) 49 (66.2%) 56 (73.7%) 39 (23.9%)
Specific diagnosis (% of total last biopsies before graft loss)b 100 (69.4%) 29 (59.2%) 44 (78.6%) 27 (69.2%)
Any rejection 76 (52.8%) 24 (49.0%) 30 (53.6%) 22 (56.4%)
Borderline changes 20 (13.9%) 6 (12.2%) 8 (14.3%) 6 (15.4%)
Acute TCMR 50 (34.7%) 18 (36.7%) 20 (35.7%) 12 (30.8%)
Acute ABMRa 25 (18.8%) 8 (17.8%) 10 (19.6%) 7 (18.9%)
Transplant glomerulopathy 32 (22.5%) 0 (0.00%) 19 (33.9%) 13 (35.1%)
De novo or recurrent glomerular disease 17 (11.8%) 2 (4.08%) 10 (17.9%) 5 (12.8%)
PVAN 8 (5.56%) 3 (6.12%) 5 (8.93%) 0 (0.00%)
IF/TA grade 2Y3 (% of total biopsies) 55 (38.2%) 2 (4.08%) 30 (53.6%) 23 (59.0%)
Presence of a specific diagnosis (% of total biopsies) 100 (69.4%) 29 (59.2%) 44 (78.6%) 27 (69.2%)
With IF/TA 0Y1 66 (66.0%) 28 (96.6%) 22 (50%) 16 (59.3%)
With IF/TA 2Y3 34 (34.0%) 1 (3.4%) 22 (50%) 11 (40.7%)
Absence of a specific diagnosis (% of total biopsies) 44 (30.6%) 20 (40.8%) 12 (21.4%) 12 (30.8%)
With IF/TA 0Y1 23 (52.3%) 19 (95.0%) 4 (33.3%) 0 (0.0%)
With IF/TA 2Y3 21 (47.7%) 1 (5.0%) 8 (66.7%) 12 (100%)
Specific diagnoses are TCMR, changes suggestive of acute ABMR, transplant glomerulopathy, PVAN and de novo or recurrent glomerular disease.
a C4d staining was available in 133 of 144 biopsies.
b Different specific diagnoses were sometimes present within a single biopsy (e.g., combined changes suggestive of acute ABMR and acute TCMR, de novo
or recurrent glomerular disease with borderline changes, acute ABMR and transplant glomerulopathy).
TCMR, T-cellYmediated rejection; ABMR, antibody-mediated rejection; PVAN, polyomavirus-associated nephropathy; IF/TA, interstitial fibrosis/
tubular atrophy.
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FIGURE 3. Histology of last renal allograft biopsies according to time after transplantation of graft loss. A, Kaplan-Meier
survival curves illustrate the association between IF/TA grade and death-censored graft survival in all last posttransplant
biopsies, according to the selected specific disease processes present in these last biopsies. N=738 biopsies for clinical
indication. adjHR and P values were corrected for age of donors and recipients, transplant year, type of immunosuppression
and time after transplantation of the biopsy. B, attributed causes of kidney transplant failure according to the histological
diagnosis of the last biopsy. N=144 last biopsies for clinical indication within the last 2 years before graft failure. ^Most
patients (58.3%) with transplant glomerulopathy experienced coexisting other specific diseases (including TCMR and
changes suggestive of acute ABMR). Eight biopsies with transplant glomerulopathy experienced also de novo or recurrent
glomerular disease, which was considered the primary cause for graft loss. *One biopsy with PVAN also experienced
recurrent membranoproliferative glomerulonephritis, which was considered to be the primary cause of graft loss. gs,
glomerulosclerosis; IF/TA, interstitial fibrosis/tubular atrophy; adjHR, adjusted hazard ratios; TCMR, T-cellYmediated re-
jection; ABMR, antibody-mediated rejection; PVAN, polyomavirus-associated nephropathy.
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grafts had primary nonfunction caused by cortical necrosis,
acute tubular necrosis, hemodynamic shock, renal vein
thrombosis, and vena cava superior syndrome; one patient
had thrombi in the biopsy at 3 months without a clear cause
and failed subsequently; and two had extensive glomer-
ulosclerosis. The other 10 of 21 (i.e., 6.9% of the total cohort of
patients with biopsies before graft loss) patients who failed
without specific disease had extensive interstitial fibrosis and
tubular atrophy without a clear cause as the single identified
cause of graft loss (Table 2; Fig. 3B).
Chronic histological damage was often present to-
gether with a specific diagnosis, especially late after trans-
plantation (Table 2). A total of 40.7% (N=11/27) of patients
with a specific diagnosis, and who lost their grafts after
5 years, developed interstitial fibrosis and tubular atrophy
grades 2 to 3 in the last biopsy, and 77.8% (N=21/27) devel-
oped greater than 50% globally sclerosed glomeruli. In total,
81.5% (22 of 27) of these patients with a specific diagnosis
before graft loss experienced extensive chronic damage (glo-
merulosclerosis or interstitial fibrosis or tubular atrophy) in
the last biopsy. Moreover, 100% of biopsies (N=12/12) with-
out specific diagnosis showed extensive interstitial fibrosis and
tubular atrophy (grades 2Y3) in the last biopsy before late graft
loss, and 67% (8 of 12) experienced glomerulosclerosis greater
than 50% (Table 2).
Of the 56 patients who lost graft function without
prior renal allograft biopsy, 24 (42.9%) lost graft function
within the first days and weeks after transplantation and in
83.3% (20 of 24), the cause was clear: 11 experienced a renal
vein thrombosis, 3 experienced a renal artery thrombosis, 2
experienced graft arterial bleeding, and 4 showed another
reason for graft dysfunction. In only four patients (16.7%),
the cause of early graft loss remained unknown. Later after
transplantation however (91 year after transplantation), in
26 (81.3%) of 32 patients the reason for graft loss remained
unknown because no biopsies were performed. In two cases,
graft loss was caused by stopping immunosuppressants
completely (therapeutic non-adherence), in two cases the
grafts were removed because of intragraft malignancy, one
patient likely experienced a recurrent glomerular disease that
was not biopsied, and one patient developed multi-organ
failure subsequent to liver failure.
Risk Factors for Chronic Histological Damage
in Late Biopsies
Finally, as extensive chronic histological damage was
independently associated with graft outcome and was pres-
ent in most grafts failed after the first year after transplan-
tation, we evaluated the clinical determinants of extensive
scarring (Table S4, SDC, http://links.lww.com/TP/A987). In
the last biopsies performed after the first year posttransplant
(N=341), transplant glomerulopathy associated significantly
with extensive scarring (28.5% of patients with extensive
scarring experienced transplant glomerulopathy vs. 18.5%
in the absence of extensive scarring; P=0.04), as well as de-
layed graft function (respectively, 18.0% vs. 10.8%; P=0.047)
and older donor age (respectively, 41.7T14.4 vs. 35.9T15.4;
P=0.0005). Interestingly, previous or ongoing acute ABMR
and TCMR were not associated with extensive scarring in
these last biopsies. Of all last biopsies with extensive scarring
performed after 1 year (N=195), 151 (77.4%) showed at
least one episode of a specific diagnosis before or at time of
this last biopsy (including borderline changes and TCMR),
which could suggest that these disease processes led to the
extensive scarring. However, also in last biopsies without
extensive scarring, specific diagnosis were made prior or at
the time of these last biopsies (106/146; 72.6%), which was
not different compared to patients with extensive scarring
(P=0.31). The sum of the prevalence of the different specific
diseases was higher than the number of patients with a specific
disease at any time point after transplantation, which related
to the fact that patients sometimes experienced different
specific diseases simultaneously or in subsequent biopsies.
DISCUSSION
The current European study, in a country with uni-
versal, law-enforced health insurance and full lifetime re-
imbursement of immunosuppressive agents for transplant
recipients elucidates the association of late kidney transplant
histology with renal allograft survival. We demonstrated that
the extent of chronic histological damage, adjusted for time
after transplantation and for the presence of specific dis-
eases, is a significant determinant of kidney transplant
outcome. We confirm previous American and Canadian
studies that show the importance of specific histological
diagnoses for graft outcome (2, 3).
However, our study illustrated that in the absence of
chronic tubulointerstitial damage, specific disease processes
generally have a good prognosis. In the presence of extensive
chronic tubulointerstitial damage, kidney outcome was gen-
erally bad, irrespective of whether a specific diagnosis is made
or not. Specific diagnoses were made in most biopsies per-
formed within 2 years before graft loss. In patients who lost
their graft, TCMR, changes suggestive of acute antibody-
mediated changes, and transplant glomerulopathy were the
prominent features in 52.8% of the last biopsies before graft
loss. This is in line with previous literature, where rejection
phenomena were the attributed cause of graft loss in 35.2% to
64% of the cases (2, 3). The reason why our study could
demonstrate the significant and independent impact of
chronic damage and specific disease processes, and previous
studies could not (3), is likely to be found in the larger patient
cohort and the longer follow-up time, which led to a markedly
higher number of late graft losses in patients with biopsies
later than 1 year (N=144 vs. 50) and thus better statistical
power in multivariate analysis.
Our study thus illustrates that not only the specific
disease process but also the extent of chronic damage should
be taken into account when evaluating transplant kidney
biopsies for prognostication and likely for therapeutic
decision-making. Very recently, this was also a conclusion of
a study on TCMR, where the development of subsequent
chronic damage determined the prognosis, and not the oc-
currence of the rejection in itself (8). Conversely, because also
the presence of a specific diagnosis significantly impacts on
outcome in patients with chronic histological damage, it is
essential to identify the underlying disease process and treat
this adequately. Evaluating chronic damage without evalua-
tion of the co-occurring disease process also withholds nec-
essary therapies to halt or slow the injury process. The
histological picture of a kidney allograft is thus often not one-
dimensional, and treatment algorithms and outcome studies
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should recognize and reflect this complexity. In addition, the
extent of chronic histological damage could be used for risk
stratification in interventional trials for specific diseases in
kidney transplants.
This importance of chronic damage, next to diagnosis
of the specific disease, is supported by recent updates in
the classification of native glomerular diseases. Based on
large studies, it is clear that the prognosis of, for example,
diabetic nephropathy, IgA nephropathy, focal sclerosis, and
of ANCA-associated vasculitis is dependent on the extent
of chronic damage, which is taken into account in these
classifications (9Y14).
A yet unanswered question is whether chronic damage
relates to the concomitant specific disease process or not.
Although the current study is not able to answer this ques-
tion thoroughly, there was no significant overrepresentation
of any specific diagnosis in patients with chronic damage
versus without chronic damage. Prior disease processes, in-
cluding acute rejection, calcineurin inhibitor nephrotoxicity,
aging, chronic ischemia, ischemia-reperfusion injury,
postrenal problems, and infections could all contribute to this
chronic damage (7, 15Y18). Because extensive scarring is sig-
nificantly associated with graft outcome, graft fibrosis as
nonspecific consequence of many injury types should remain
the focus of further research, for example, by studying subtle
and subclinical inflammation (18). In the present analysis, we
confirm (19) that arteriolar hyalinosis in for-cause biopsies is
associated with better postbiopsy allograft survival. The rea-
son for this unexpected finding is not clear and warrants
further study.
The fact that not all patients had a graft biopsy within
a reasonable time frame before graft loss, and absence of
protocol biopsies, is a drawback of the current study. Sub-
clinical events that ultimately contribute to graft loss thus
remained undetected. Because clinicians likely select those
patients for late biopsies who have a higher pretest proba-
bility of a specific and treatable disease process, selection
bias is inherent to the current analyses and may have led to
overestimation of the prevalence of specific diagnoses before
graft loss. We demonstrated that this is not so much the case
within the first year after transplantation, where 83.3% of
losses without histological diagnosis were well explained by
other medical conditions. Late after transplantation, how-
ever, in 81.3% of cases, no cause of graft loss could be put
forward in the absence of indication biopsies. In addition,
by focusing on last biopsies, the true impact of earlier in-
flammatory lesions could have been underestimated, as it is
well established that inflammatory lesions wane over time
after transplantation (20). By using the last biopsy in a ret-
rospective manner, there is some ascertainment bias that the
more distant the biopsy, the better the patients would have
performed. However, because the analysis focuses on the
postbiopsy allograft survival and not survival after time
of transplantation, and because time from transplantation
and the number of previous biopsies were taken into ac-
count, this bias does not decrease the clinical applicability
of this analysis.
Furthermore, it has to be acknowledged that not all
patients were treated with the currently used powerful im-
munosuppressive regimens, and that modern-type antibody
testing, electron microscopy, and screening for PVAN were
not available in the current study cohort. The underlying
disease process could thus have been missed in some pa-
tients, and the impact of, for example, C4d-negative ABMR
(21, 22) and of PVAN on graft outcome is therefore under-
estimated in the analyses. However, the actual prevalence of
PVAN is low even with current screening strategies, and the
true prevalence of C4d-negative ABMR in kidney transplants
without preformed donor-specific antibodies remains to be
evaluated (23, 24). Finally, the kidney grafts in the current
study were almost exclusively from deceased donors, and
nonYheart beating donationwas not performed in this patient
cohort. Validation of our findings is warranted in patient co-
horts more representative for current clinical practice and
treated with current immunosuppressive protocols.
CONCLUSION
In conclusion, the current study demonstrates that
renal allograft loss is multifactorial and preceded by a com-
bination of late TCMR, changes suggestive of acute ABMR, de
novo or recurrent glomerulopathy, or PVAN, together with
chronic histological damage. This chronic histological damage
should remain the focus of further research. Chronic histo-
logical damage should be taken into account in prognostica-
tion of graft outcome and could be important in treatment
algorithms of specific disease processes.
MATERIALS AND METHODS
Biopsies and Histological Scoring
All posttransplant renal allograft biopsies performed in this cohort, until
time of data extraction, were included. Posttransplant biopsies were per-
formed for clinical indication, at time of graft dysfunction. No posttransplant
surveillance (‘‘protocol’’) biopsies were performed in this patient cohort. Slides
containing 4 to 10 paraffin sections (2 Km) were stained with hematoxylin-
eosin, Periodic Acid-Schiff, and silver methenamine (Jones). An immuno-
histochemical C4d stain (monoclonal antibody, dilution 1:500; Quidel
Corporation, Santa Clara, CA) was performed on frozen tissue. One pathol-
ogist (E.L.) retrospectively reviewed all biopsies. The severity of histological
lesions was semiquantitatively rescored according to the revised Banff criteria
(24Y26). In addition, the number of sclerosed glomeruli was scored separately
(0=0%; 1=1%Y25%; 2=25%Y50%; 3=950% glomerulosclerosis), and peri-
tubular capillaritis was scored based on the recently proposed score (25). Total
inflammation was evaluated in the whole cortex using the total i score (total i
0=G10%; 1=10%Y25%; 2=25%Y50%; 3=950%) (25). C4d deposition in the
peritubular capillaries was scored from 0 to 3 (with 0=negative, 1=G25%,
2=25%Y75% and 3=975% of peritubular capillaries positive), given the use
of immunohistochemistry on frozen tissue for this marker. Changes suggestive
of acute ABMR were defined as presence of C4d deposition in peritubular
capillaries grade greater than 1 together with any microcirculation inflam-
mation (glomerulitis or peritubular capillaritis). Transplant glomerulopathy
was considered as a separate entity, as no data on donor-specific human
leukocyte antigen antibodies or electron microscopy were available for this
patient cohort.
Data Collection and Statistical Analysis
All clinical data were prospectively collected in electronic clinical patient
charts, which were used for clinical patient management as well as were
directly linked to the database used in this study. This clinical database was
transferred to SAS data files (SAS Institute, Cary, NC) at the time of anal-
ysis. For variance analysis of continuous variables in different groups, non-
parametric Wilcoxon-Mann-Whitney U, nonparametric analysis of variance,
and parametric one-way analysis of variance were used as appropriate. Di-
chotomous variables were compared using chi-square testing. Multivariate
Cox proportional hazards analysis with backward variable selection was
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performed to evaluate the clinical and histological determinants of death-
censored graft survival. Log(-log(survival)) versus log(time) plots showed
no nonproportionality of hazards. Repeat transplants within the inclusion
time frame were regarded as separate entities in statistical analysis. Type
of immunosuppression was dichotomized (baseline mycophenolic acid +
tacrolimus with or without steroids, versus all other combinations). Kaplan-
Meier curves and log-rank testing were used to plot graft survival. All tests
were two-sided and P values of less than 0.05 were considered to be sta-
tistically significant. Analyses were performed with SAS (version 9.2; SAS
institute, Cary, NC) and GraphPad Prism (version 6; GraphPad Software,
San Diego, CA).
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